Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 2520) to provide for the collection and maintenance of human cord blood stem cells for the treatment of patients and research, and to amend the Public Health Service Act to…
Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 2520) to provide for the collection and maintenance of human cord blood stem cells for the treatment of patients and research, and to amend the Public Health Service Act to authorize the C.W. Bill Young Cell Transplantation Program.
Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days within which to revise and extend their remarks on this legislation and to insert extraneous material on the bill.
Mr. Speaker, I yield myself such time as I may consume.
Mr. Speaker, I rise in strong support of H.R. 2520, the Stem Cell Therapeutic and Research Act of 2005, legislation I have cosponsored along with the honorable gentleman from New Jersey (Mr. Smith), who is in the Chamber. This would expand the number of stem cell options available to Americans suffering from life-threatening diseases.
Every year, nearly two-thirds of the approximately 200,000 patients in need of a bone marrow transplant will not find a marrow donor match within their families. These patients must rely on the help of strangers to donate bone marrow for a transplant. To assist these patients, Congress established the National Bone Marrow Registry to quickly match donors to patients. Through this program, Congress made a significant investment to connect patients with a rich source of stem cells that offer immediate clinical benefits.
With scientific advances, Congress must now make changes to reflect new
therapeutic options. Cord blood units have been shown to be a suitable alternative to adult bone marrow for the treatment of many diseases, including sickle cell anemia. This is an especially important advancement for those Americans who have desperately searched for a marrow donor but could not find a match with even the help of the National Bone Marrow Registry. As another rich source of stem cells, a cord blood transplant is another chance at life for many of these patients.
The bill before us today builds on the critical investments we have made over the past 2 decades with the National Bone Marrow Registry and retools this design into a new, more comprehensive stem cell transplantation program, which will include not only bone marrow but also cord blood units. Through a competitive contracting process, this new program will allow transplant doctors and patients to access information about cord blood units and bone marrow donors, at the same time, and I want to emphasize at the same time, through a single point of access. This new program does not create a preference for either cord blood or bone marrow. Instead, it will provide comprehensive information about both sources of stem cells to doctors and patients and allow them to make the most clinically appropriate choice.
I want to recognize the gentleman from Florida (Mr. Young) at this time. It was the gentleman from Florida's (Mr. Young) drive, when he was chairman of the Committee on Appropriations, and his steadfast support for the idea of a national registry for bone marrow that led to the program's creation. The gentleman from Florida's (Mr. Young) lifesaving work is evident again today in the program's new design and goals. I am pleased that Congress is recognizing his dedication by naming this new program the C.W. Bill Young Cell Transplantation Program. I do not see the gentleman from Florida (Mr. Young) in the Chamber, but at the appropriate time when he does arrive, I hope that the body will give him a standing ovation for his work in this area.
The capacity to search for cord blood units through a national network of cord blood banks will help facilitate cord blood transplants. We also need to expand the inventory of cord blood units so that more transplants can occur. The bill before us today authorizes a new grant program to provide subsidies to cord blood stem cell banks to expand the inventory of high-quality cord blood units that will be included in the new, expanded Cell Transplantation Program. I think that number is 150,000 units, which is a significant increase.
In addition to expanding the number of cord blood units available for clinical use to save lives today, the bill would also expand the number of cord blood units available for research. Research on adult stem cells holds the potential to develop new cures for many diseases, as well as to expand our knowledge of how human beings develop and the body works.
I would also like to make a personal aside here. My wife and I are expecting a child in September, and we are working with the cord blood people as we speak so that my son, and it is going to be a little boy and we are going to name him Jack Kevin, that we are going to save his cord blood so that some day in the future, if he needs it, it will be available. So in this case I can honestly say, in addition to sponsoring the bill, I am beginning to practice what I am preaching today.
It is not enough to connect patients with lifesaving donors. We also need to better understand how these patients fair when they receive the transplants. The bill would authorize research on the clinical outcomes of patients who are recipients of a stem cell therapeutic product, including bone marrow, cord blood, and other such products, from a biologically unrelated donor. It is my hope that this additional research will trigger new scientific breakthroughs to enhance and advance human life.
This is an important bill that merited many hours of negotiation, demanded the willingness of all those involved to put the interest of their patients first. I would like to thank the bill's primary sponsor, the honorable gentleman from New Jersey (Mr. Smith). I would also like to thank the gentleman from Florida (Mr. Young); the House leadership, including the honorable gentleman from Texas (Mr. DeLay); Congressional Black Caucus; the gentleman from Michigan (Mr. Dingell), the ranking Democrat on the committee; the gentleman from Ohio (Mr. Brown), the subcommittee ranking member who is here to speak on the bill; and all of the staff who have labored on this bill.
Particularly, I would like to thank Cheryl Jaeger, on my left, of my committee staff, for all of her efforts. She has been tireless in the last several months working on this bill. In the last few weeks, she has been able to forge a compromise that ultimately was acceptable to all the advocates of both bone marrow and cord blood.
We will continue to improve the legislation that moves forward so that pregnant women are informed of all of their options with respect to cord blood donation and the programmatic activities of the Cell Transplantation Program are clarified.
Mr. Speaker, at the appropriate time, I would urge all of my colleagues to support this bill. It is good legislation, well thought out, and deserving of majority support.
The Stem Cell Therapeutic and Research Act of 2005 Establishes a
Foundation for Improving Access to Lifesaving Cellular Therapy
Transplants
The National Marrow Donor Program (NMDP) is pleased that
the sponsors of the Stem Cell Therapeutic and Research Act of
2005 have taken a positive step forward toward expanding the
long-standing Congressional commitment to cellular transplant
therapies by introducing legislation to continue Federal
support for bone marrow, peripheral blood, and umbilical cord
blood transplantation and research. Through the legislation
introduced today, they acknowledge the important role
Congress has played and must continue to play in ensuring
that the more than 14,000 Americans in need of these types of
transplants have access to them.
The bill calls for Federal dollars to increase the number
of umbilical cord blood units available for transplant and
research. Currently, there are 42,000 units available through
the existing National Bone Marrow Donor Registry (National
Registry), which also lists more than 9 million adult donors
worldwide. With additional umbilical cord blood units added
to this registry, more Americans who would otherwise not be
able to locate a suitably matched adult donor will be able to
find hope through a cord blood transplant. The NMDP estimates
that with access to the existing adult donors and units, the
addition of 150,000 cord blood units listed through the
existing registry will provide a match for approximately 95
percent of Americans.
By designating the existing National Registry as the C.W.
Bill Young Cell Transplantation Program, the sponsors have
acknowledged Representative Young's unwavering commitment to
the National Registry and its growth. In 1986, Representative
Young's vision of a single integrated national bone marrow
donor registry became a reality. Since that time, the
National Registry has facilitated more than 21,000 unrelated
transplants involving cord blood, bone marrow, and peripheral
blood. It now includes more than 5 million U.S. adult
volunteer donors and has links to another 4 million
worldwide. As evidence supporting cord blood as a source of
the same cells found in bone marrow and peripheral blood has
grown, the National Registry, operated by the NMDP, has
expanded to include more than 42,000 cord blood units through
the NMDP's partnership with 14 of the 20 U.S. public cord
blood banks. We join the sponsors in saluting Representative
Young's dedication to helping the thousands of Americans in
need of these types of transplants.
The expansion of the Program will benefit patients most if
they are able to access the new sources of cells easily and
efficiently. The NMDP supports the intent of the sponsors to
provide patients and physicians with access to cord blood,
bone marrow, and peripheral blood stem cells through a single
point of access. To ensure the continued expansion of cord
blood transplants, it is important that patients and
physicians can search for all of these sources through a
single registry, compare each source of cells for transplant
quickly and efficiently, and obtain the cells once the search
process is finished. One-stop-shopping to obtain information
and logistical support is a critical component of the success
of transplantation regardless of whether adult donors or cord
blood units are used. The bill recognizes this need by
calling for a single point of access for these activities to
build upon the National Registry. Using the current registry
as a basis for the new program will ensure that limited
resources are dedicated to increasing the availability of
matches and not in reinventing new bureaucracies.
Although this bill is a step in the right direction, it is
critically important that the Program also have the authority
to establish criteria and standards that provide transplant
physicians with the assurances they
need to be confident that when they compare various cord
blood units and/or adult donors, they have the same type of
information about each unit or donor. In addition, the NMDP
urges members to recognize that transplant patients may
encounter other barriers to accessing cellular therapy
transplants. The need for assistance in addressing barriers
to access should be extended to all recipients of transplants
under this program, regardless of cell source. Physicians and
patients must be able to receive all of the services
necessary for a successful transplant, including distribution
coordination, patient counseling, translation assistance,
testing, insurance coordination, and other patient advocacy
services. We look forward to working with the sponsors and
the Department of Health and Human Services to strengthen
these provisions of the legislation.
The NMDP applauds the sponsors for undertaking this
important public health initiative. Through their leadership,
thousands of Americans who might otherwise die will have
access to lifesaving bone marrow, peripheral blood stem cell,
and cord blood transplants.
Mr. Speaker, I ask unanimous consent that debate on this motion be extended by 20 minutes, equally divided between myself and the gentleman from Ohio (Mr. Brown).
Mr. Speaker, I yield 5 minutes to the gentleman from New Jersey (Mr. Smith), the original author of the bill and my cosponsor.
Mr. Speaker, I yield 2 minutes to the gentleman from New Jersey (Mr. Ferguson), a member of the Committee on Energy and Commerce.
Mr. Speaker, I yield 2 minutes to the distinguished gentleman from Florida (Mr. Weldon), a doctor, and one of our more thoughtful Members on this subject and somebody who has given a lot of time to it.
Mr. Speaker, I yield 2 minutes to the gentleman from California (Mr. Daniel E. Lungren).
Mr. Speaker, I yield 15 seconds to the gentleman from New Jersey (Mr. Smith), very briefly.
Mr. Speaker, I yield 2 minutes to a member of the committee, the distinguished gentleman from Pennsylvania (Mr. Murphy).
Mr. Speaker, I yield 1 minute to the gentleman from Georgia (Mr. Gingrey).
Mr. Speaker, I yield 1 minute to the distinguished Majority Leader of the great State of Texas (Mr. DeLay), Fort Bend County, Sugarland.
Mr. Speaker, I yield 1 minute to the gentleman from Georgia (Mr. Price).
Mr. Speaker, I yield 1 minute to the gentleman from Indiana (Mr. Pence), the distinguished leader of the Republican Study Committee.
(Mr. PENCE asked and was given permission to revise and extend his remarks.)
Mr. Speaker, I have three willing speakers now and more on the way.
Mr. Speaker, I yield 1 minute to the gentleman from Pennsylvania (Mr. Pitts), a member of the committee.
Mr. Speaker, I yield 1 minute to the gentleman from Delaware (Mr. Castle), the distinguished Congressman and former Governor of the first State of our Union.
Mr. Speaker, I yield 1 minute to the gentlewoman from Pennsylvania (Ms. Hart).
Mr. Speaker, I have one speaker remaining, and I will close.
Mr. Speaker, I yield 2 minutes to the gentleman from Florida (Mr. Weldon).
Mr. Speaker, I yield 1 minute to the distinguished gentleman from the Keystone State of Pennsylvania (Mr. Weldon).
Mr. Speaker, how much time remains?
Mr. Speaker, I yield myself the balance of my time, and I want to thank the majority leader and the Speaker for bringing these two bills to the floor today.
The first vote we will have is on the cord blood and bone marrow bill, H.R. 2520. This bill, by itself, is an extremely important advance for those of us that believe you can use medical research ethically to help find cures for existing disease and enhance human life both now and in the future.
I am, obviously, as one of the original sponsors of the bill, going to vote for it and encourage all the Members on both sides of the aisle to vote for its. It is a good piece of legislation and, by itself, is a major advancement in the state of the art that we have today.
The next debate that we will have is on the Castle-DeGette bill which is another form of stem cell research, embryonic stem cell. That issue is much more controversial, but on its own merit that bill itself deserves a serious debate. And while it is not yet time to debate that bill, at that time I will announce that I will vote for that bill also.
So I hope we can do first things first. Let us pass in a strong bipartisan fashion the Smith-Barton-Young adult cord blood bone marrow bill, and then go on to the next issue.